Compare Illumina, Inc. (ILMN) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Illumina, Inc. trades at $181.13 (market cap $27.94B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $32.51. The key difference: Illumina, Inc. is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| ILMN | TMF | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $194.33 | $44.14 |
52-Week Low | $91.00 | $31.85 |
Enterprise Value | $29.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
TMF, the Direxion Daily 20+ Year Treasury Bull 3X ETF, trades at $32.66, down 2.07% on the day, reflecting a bearish technical trend with moving averages signaling sell pressure. The fund provides 3x daily leveraged exposure to long-term U.S. Treasury bonds, making it highly sensitive to interest rate movements. Recent news highlights its significant long-term decline, with a $10,000 investment five years ago now worth approximately $1,527, underscoring the risks of daily leverage reset in volatile markets.
The outlook for TMF hinges on the direction of long-term bond yields and Federal Reserve policy. While some analysts see potential at the lower end of the trading range, the fund's structure makes it unsuitable for long-term holding due to volatility decay. Key risks include rising interest rates, inflation expectations, and the inherent leverage mechanism that amplifies losses. It remains a high-risk, tactical instrument for short-term traders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
